XERS Xeris Biopharma Holdings Inc

$XERS They have to say "we're not for sale", and it means absolutely nothing... They need to float a price before anything becomes real. That's when we will know whether it's a real offer...

$XERS A big bidding war would be nice. $40.00 or more. if any less don't sell. I am good to wait. I have been waiting for 7 years. I can wait a little longer.

$XERS My thoughts re the price increase the last few trading days is that the stock is being accumulated in anticipation of a buyout in the $24 price range.. I see a rapid jump in share price in the coming days. This is time to accumulate a substantial position. There are so many positive catalysts that can propel the stock price into the $20’s.. An easy double here no matter if takeover takes place or not! Bought huge position today..

$XERS Crazy AF if you shorting here or selling. The risk is almost all gone now. We will be EPS+ & CF+ with 87% margins and heavy BO rumors. They can say “not for sale” just to save face and keep employees working but when it come down to it everyone has a price and now that’s the cats out of the bag other companies may want to join in and the sharesholders have the final say! $6B+ minimum for the going offer.

$XERS Maybe it was me seeing things, but I noticed some signals for Q3 from the HC Wainwright call: - John: We expect a 33% growth this year (pause) at least - Steve: We invested in the beginning of this year to double our sales team. We are now seeing Recorlev growth play out as we expected, maybe even better than we anticipated Both said this while smiling.

$XERS To be able to acquire the XP-8121 & Recorlev duo (and Xeris in general), you should be able to raise approximately $40 per share today, because by 2030, based on projected revenue of $700–800M, plus XP-8121 and nearly 90% margins, the business could naturally be worth around a $12B market cap, or approximately $70 per share. And potentially twice that in a buyout.

$XERS H Lundbeck (HLBBF) has expressed interest in purchasing the commercial-stage drugmaker. The Danish pharma firm has been working with advisers to explore an acquisition of Chicago-based Xeris (XERS), according to a Bloomberg report on Tuesday, which cited people familiar with the matter. A spokeswoman for Xeris (XERS) told Bloomberg the company is “not for sale” and is “laser focused on improving patient lives by developing and commercializing” its medicines. Xerix (XERS) has a market cap of $1.79 billion, while Lundbeck has a value of 43.3 billion Danish kroner ($6.6 billion). Very

$XERS I've already mentioned this before... Institutional investors would very likely continue replacing retail investors at any price point - $20, $40, $60, all the way into the combined XP-8121 & Recorlev era in 2030. It's a no-brainer. The price tag isn't what matters, what matters is how big the underlying opportunity. XP-8121 would very likely be the only once-weekly injectable levothyroxine option(specifically treatment), for many years to come, with 72% of patients in the clinical stage showed a strong preference for XP-8121 over the existing oral option. That represents a multibillion-dollar opportunity, even if we consider only the U.S. market. Meanwhile, Recorlev is very likely the fastest-growing direct cortisol-lowering treatment, with significant room to continue growing strongly for many years(thers isn't any new direct coristol-lowering treatment for years going forward) That's an exceptional opportunity.

$XERS Xeris is being noticed!!! Corient Private Wealth LP Acquires 184,126 Shares of Xeris Biopharma Holdings, Inc. $XERS Written by MarketBeat September 26, 2026 1,397,050 Shares of Xeris Biopharma Holdings, Inc. $XERS Acquired by Bank of America Corp DE Written by MarketBeat September 27, 2026

$XERS just buy back in the 9s lol, probably as good as it gets, talking it down is not working. Every dip will be bought now that the floor has been laid.

$XERS 100% agreed, the floor has been laid, this has become unshortable unless for a quick intraday short on bad macro days. This stock will be hot for the next few years and BO can happen anytime, every news development will change its dynamics and price. swing and accumulate.

$XERS $20.27 *I’m not posting because there’s nothing to post. Steady growth. Big catalyst incoming. It’s not sexy but I don’t need sexy, I need sustainable returns that beat market baskets.

$XERS no doubt someone large is pushing this up, every EOD last 10 minutes large orders of 50k or 100k pushing bid/ask up into the close, regardless whether it's green or red at that time

$XERS I think we still need phase 3 launch news before an official rip but this is nice. Very nice.

$XERS Ok, even I will say something is cooking. It's the big buys at these higher prices, one right after another. Hope we've found a new floor.

$XERS We ain't seen nothing yet... Last year's peak -> $10 - November 2025 Based on the following fundamentals: A)$285–290M revenue (finished at $293M) B)Recorlev reached $139M by year-end C)A very successful Phase 2 trial for XP-8121. This year's main fundamentals -> A)$385–390M revenue B)QoQ-growing profits at this stage C)Recorlev approaching $250M (massive growth) D)XP-8121 should begin Phase 3 (multibillion-dollar blockbuster potential) Xeris in 2026 is double (possibly more) the asset it was in 2025. Keep it in mind.

$XERS I've converted. New floor. Significant interest. Big buys at higher prices. The foundation feels stronger today than it did the last two times this hit 10. I guess, after all, she is a princess.

$XERS So this spikes to over $11 in 6 x the normal volume then goes red ? Make it make sense !.. UGGH

$XERS Agreed, the stock is not sexy but will “slowly” grow. People underestimate Recorlev and overestimate the Phase 3 expenses. The team highlighted that Phase 3 will be 70M total, of which 25M in 2026, half of the remaining in 2027 and the other half in 2028. If we add those expenses in, consider the 0.65M in quarterly savings from paying of the convertibles, and assume a relatively slow growth for Recorlev for coming quarters (10.9% avg) even though we will start seeing the sales force effects, you would have only 1 quarter of a “bad” EPS around 0 or 0.01. And that is if quarter 3 already has 12.5m in Phase 3 expenses. I was pleased to hear Levo is only going to cost 70M in R&D in coming years. Lets see how they execute in Q3 which probably will be the turning point.

$XERS if everything Im reading is true, thank god allison was quick to shut down any rumors. XP-8121 is a sure bet and there will be plenty of interest. we would be selling ourselves short if we accepted a buyout at this time.